DSSG Group: Genitourinary

Pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma

To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma(RCC)

Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA).

Metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy.

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC with respect to overall survival (OS) and to radiographic progression-free survival (rPFS)

High risk localised prostate cancer, deemed suitable for SBRT radiotherapy and planned for 12 – 36 months androgen deprivation therapy

This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer.

Advanced / metastatic genitourinary cancer (including prostate, kidney, urothelial tract, testicular and/or penile cancers)

To evaluate the feasibility of introducing a men’s cancer survivorship program into routine follow up care in patients with advanced genitourinary malignancies.

Castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors

The purpose of the trial is to evaluate the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability.

Testicular cancer treated with either surgery, chemotherapy or radiotherapy and completed 5 years of surveillance.

To determine incidence of late complications in testicular cancer survivors of Ireland.

Prostate Cancer being Treated with Stereotactic Body Radiotherapy

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

Metastatic Castrate Resistant Prostate Cancer (mCRPC).

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC).

High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011)

The purpose of this trial is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.